Palmer: There are lots of subpopulations within this disease, and there are lots of gaps in our knowledge still about how some of those subpopulations behave. So, we as a company, with the help of many of our physicians, continue to invest in new clinical trials to produce more data in those areas—to see how patients do with various sometimes comorbidities but other forms of these diseases.
We do that through clinical trials, we do it through registries. As you heard Dr. Tapson say, we’ll continue to report our data, both from clinical trials where we complete studies. We’ve completed a number this year in for the pulmonary indication, looking at right ventricular function. But we have others that are continued to roll out over the next 5 years, and we are following patients longer and longer.
So, you know the initial trials in this area focused on short periods of time—6 months. We now have data actually from the SERAPHIN trial that was referenced earlier, where we’ve been following patients for up to 7 years. And we see what happens to these patients with treatment with the disease over longer and longer periods of time. And we’ll continue to release that data as it becomes available.
Tapson: And I wouldn’t just expect a family practice or primary care physician to be able to stay up on all these data. They have so much to do and so many things they need to know. Primary care is very challenging nowadays. If they can be aware of the disease, aware of pulmonary hypertension symptoms, unexplained dyspnea, maybe not being overweight or in poor condition or from some other primary disease. Just simple things on an exam that some people may not notice.